Peptide (e.g., Protein, Etc.) Containing Doai Patents (Class 514/1.1)
  • Patent number: 10836791
    Abstract: The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for lightening natural skin color.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: November 17, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Marc Heidl, Eileen Jackson
  • Patent number: 10836872
    Abstract: A visible light-curable chitosan derivative, a hydrogel thereof, and a preparation method therefor are disclosed. The visible light-curable glycol chitosan derivative is curable by light in the visible light range and has a wound healing activity. A hydrogel obtained by cross-linkage of the visible light-curable glycol chitosan derivative using visible light has a wound healing effect per se, and further, a hydrogel obtained by cross-linkage in a combination of one or more growth factors has an excellent wound healing effect. In addition, a glycol chitosan hydrogel that can prevent the denaturation of contained drugs and growth factors due to the cross-linkage by visible light and is optimized for application to a wet dressing dosage form can be prepared.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: November 17, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMY COOPERATION
    Inventors: Dae Hyeok Yang, Heung-Jae Chun, Dong In Seo
  • Patent number: 10834908
    Abstract: Disclosed is a non-human animal comprising a genetic construct expressing TCR? and TCR? genes and wherein the animal comprises a null-mutated Rag-2 locus. Described herein is also a NOD.Rag2?/? mouse expressing a transgenic ?,? T cell receptor. The animals spontaneously develop chronic inflammation and fibrosis, and are useful as animal models of fibrotic disease.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 17, 2020
    Assignee: INFICURE BIO AB
    Inventor: Dan Holmberg
  • Patent number: 10829539
    Abstract: The present invention relates to improved methods for the recombinant production of von Willebrand factor (vWF) in a bioreactor by separating different multimeric forms of vWF with different molecular weight during fermentation.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: November 10, 2020
    Assignee: CSL Limited
    Inventors: Stefan Debus, Holger Lind
  • Patent number: 10828253
    Abstract: The present disclosure relates to a composition for injection, which comprises a pharmaceutically acceptable salt of a compound represented by Formula 1 and one or more selected from mannitol, trehalose, lactose and glucose as a stabilizing agent, having improved stability.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: November 10, 2020
    Assignee: HK INNO.N CORPORATION
    Inventors: Hyo Jin Kim, Sung Jun Kim, Min Kyoung Lee, Sung Ah Lee, Mi Young Yoon
  • Patent number: 10821375
    Abstract: The present invention discloses a method to continuously manufacture micro- and/or nanoparticles of single component particles or multi-component particles such as particulate amorphous solid dispersions or particulate co-crystals. The continuous method comprises the steps of 1. preparing a first solution comprising at least one component and at least one solvent and a second solution comprising at least one anti-solvent of the at least one component comprised in the first solution, 2. mixing said first solution and said second solution by means of microfluidization to produce a suspension by precipitation or co-precipitation, 3. feeding said suspension to a filtration system to obtain a concentrate stream, 4. feeding said concentrate stream to a spray dryer, 5. atomizing said concentrate stream using at least one atomization nozzle, 6. drying said atomized concentrate stream to obtain particles, and 7. collecting said particles.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: November 3, 2020
    Assignee: Hovione Scientia Limited
    Inventors: Tiago Fonseca, Iris Duarte, Márcio Temtem, João Vicente
  • Patent number: 10821160
    Abstract: Variant Erwinia chrysanthemi L-asparaginases with reduced L-glutaminase activity and enhanced in vivo circulation are described as are fusion proteins containing an L-asparaginase and three tandem soluble domains of TRAIL for use in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Arnon Lavie, Hien-Anh Nguyen
  • Patent number: 10822318
    Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, R3, R4, L1, L2 and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful for labeling penicillin-binding proteins (PBPs).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 3, 2020
    Assignees: Regents of the University of Minnesota, Indiana University Research and Technology Corporation
    Inventors: Erin Elizabeth Carlson, Shabnam Sharifzadeh, Alireza Shokri, Ozden Kocaoglu, Clayton L. Brown, Jr.
  • Patent number: 10815296
    Abstract: Disclosed are drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA, also called TA-TMA) in a subject that has undergone an HSCT. Also disclosed are methods of using drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA) in a subject that has undergone an HSCT.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: October 27, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Sonata Jodele, Benjamin L. Laskin
  • Patent number: 10806732
    Abstract: An anti-neoplastic stable pharmaceutical composition comprising Temozolomide, high substituted polysaccharide phosphate in salt form, and high substituted polysaccharide phosphate in acidic form, in particular in a weight ratio of from 5 to 20% Temozolomide to 30 to 80% of polysaccharide in salt form, the reminder up to 100% being polysaccharide in acidic form. The level of 5-aminomidazole-4-carboxamide is below 0.5% by weight of Temozolomide in both the composition and the formulation disclosed. Also disclosed is a hydrogel for intrathecal administration obtainable by contacting the composition with sterile water, a method of manufacture of the composition and uses of the composition and the gel.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 20, 2020
    Assignees: Double Bond Pharmaceutical AB, Research Institute of Physical Chemical Problems of the Belarulsna State University
    Inventors: Mikalai Yurkshtovich, Dzmitry Veyeunik, Valiantsina Alinouskaya, Natalia Atrakhimovich, Iryna Halouchyk, Sergey Beliaev, Tatjana Yurkshtovich, Pavel Bychkouski, Aliaksandr Fedulau, Tatsiana Trukhachova
  • Patent number: 10799468
    Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: October 13, 2020
    Assignee: First Wave Bio, Inc.
    Inventors: Gary D. Glick, Luigi Franchi
  • Patent number: 10801024
    Abstract: Embodiments disclosed herein concern compositions and methods for treating a condition characterized by overexpression of long non-coding RNA HOTAIR. In certain embodiments, synthetic polynucleotide analogs capable of hybridizing with a target sequence domain of HOTAIR are provided. The synthetic polynucleotide analogs can be formulated into a pharmaceutical composition for treating a subject having or at risk of having a condition characterized by HOTAIR overexpression. In certain embodiments, the pharmaceutical composition can resensitize a subject to a chemotherapeutic agent. Other embodiments concern uses for HOTAIR-targeting synthetic polynucleotide analogs, including methods for determining HOTAIR expression in a sample.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 13, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Ali Rayet Ozes, Kenneth P. Nephew
  • Patent number: 10799589
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 13, 2020
    Assignee: BUZZARD PHARMACEUTICALS AB
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Patent number: 10793597
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 6, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10781158
    Abstract: Pharmaceutical formulations of tetrahydrocurcumin and liposomes are described herein. The liposomes may comprise at least a first lipid, wherein the first lipid is a phospholipid or polyenylphosphatidylcholine are also disclosed.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignee: Bhupinder Singh
    Inventor: Bhupinder Singh
  • Patent number: 10772911
    Abstract: A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: September 15, 2020
    Assignee: Advanced ReGen Medical Technologies, LLC
    Inventors: Steven John Greco, Vincent C. Giampapa
  • Patent number: 10770276
    Abstract: According to some aspects, a spectrometer is provided, the spectrometer configured to receive molecules of a plurality of metabolites including one or more molecules of a first metabolite, filter the received molecules to retain molecules of the first metabolite including a plurality of different mass isotopomers of the first metabolite, fragment molecules of a first mass isotopmer of the retained molecules to produce a first plurality of daughter ions, measure abundances of the first plurality of daughter ions as a function of daughter ion mass, fragment molecules of a second istopomer, different from the first mass isotopmer, of the retained molecules to produce a second plurality of daughter ions, and measure abundances of the second plurality of daughter ions as a function of the daughter ion mass.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Yale University
    Inventors: Richard Kibbey, Tiago Cardoso Alves, Graeme F. Mason
  • Patent number: 10751428
    Abstract: The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to ?-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 25, 2020
    Assignee: The Regents of the University of California
    Inventor: Massoud Akhtari
  • Patent number: 10744235
    Abstract: A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 18, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Lieven Elvire Colette Baert, Iksoo Chun, Guenter Kraus, Deborah M. Schachter, Qiang Zhang
  • Patent number: 10744103
    Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: August 18, 2020
    Assignee: First Wave Bio, Inc.
    Inventors: Gary D. Glick, Luigi Franchi
  • Patent number: 10723784
    Abstract: Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantation rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 28, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Peter Gottlieb, Charles Dinarello
  • Patent number: 10688106
    Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: June 23, 2020
    Assignee: FERRING B.V.
    Inventor: Joan-Carles Arce
  • Patent number: 10683363
    Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: June 16, 2020
    Assignee: The United States of America as represented by the Department of Veteran Affairs
    Inventors: Richard H. Weisbart, Robert N. Nishimura
  • Patent number: 10676749
    Abstract: Computer programs, algorithms, and methods for identifying TALE-activator binding sites, and methods for generation and use of TALE-activators that bind to these sites.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: June 9, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Morgan Maeder
  • Patent number: 10676509
    Abstract: Immobilizable antimicrobial compounds incorporating antimicrobial and/or antifouling components, as can be adhered to various device structures and components.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: June 9, 2020
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Annelise E. Barron, Andrea Statz, Nathaniel Chongslriwatana
  • Patent number: 10670592
    Abstract: Disclosed herein are systems and methods for detecting Chemical Species, Biomolecules and Biotargets (Analytes) using receptor functionalized metal nanoparticles and Dynamic Light Scattering.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: June 2, 2020
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Qun Huo, Xiong Liu, Qiu Dai
  • Patent number: 10668159
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 10654922
    Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: May 19, 2020
    Assignees: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
    Inventors: Yuefeng Lu, Jian-Feng Lu
  • Patent number: 10654893
    Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc. that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 19, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Karl Gilbert, Manav Mehta
  • Patent number: 10633428
    Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 28, 2020
    Assignee: ALBUMEDIX LTD
    Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
  • Patent number: 10632131
    Abstract: The present invention relates to controlled release systems that may be administered other than intravenously. The controlled release system is directed to active ingredients, entrapped in or otherwise incorporated in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the active ingredients are covalently bonded to the polymer carriers or polymeric devices. The controlled release systems may suitably be used to treat diseases.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: April 28, 2020
    Assignee: CRISTAL DELIVERY B.V.
    Inventors: Cristianne Johanna Ferdinand Rijcken, Martin Stigter, Josephus Johannes Maria Holthuis
  • Patent number: 10632080
    Abstract: Improved distribution can be achieved by delivering nanoparticles possessing non-adhesive surfaces via CED in a hyperosmolar infusate solution. This delivery strategy minimizes the hindrances imposed by the brain extracellular matrix and reduces the concentration of therapeutic that is confined within perivascular spaces.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: April 28, 2020
    Assignee: The Johns Hopkins University
    Inventors: Clark Zhang, Panagiotis Mastorakos, Jung Soo Suk, Justin Hanes
  • Patent number: 10632168
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 28, 2020
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard Eric Schlumpf, Robert Baratta, Shawn A. Delorey
  • Patent number: 10627402
    Abstract: Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventors: Eun Kyung Choi, Seong-Yun Jeong, Si Yeol Song, Kyoung Jin Lee, Seol Hwa Shin, Eun Jin Ju
  • Patent number: 10624913
    Abstract: The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: April 21, 2020
    Assignee: VOLANT HOLDINGS GMBH
    Inventors: Jerome Schentag, Joseph M. Fayad
  • Patent number: 10603387
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 31, 2020
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • Patent number: 10603355
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: March 31, 2020
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Patent number: 10596223
    Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: March 24, 2020
    Assignee: Xigen Inflammation Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Patent number: 10596095
    Abstract: A method for moisturizing skin using P-113 peptide, which comprises administering to the skin of a subject a composition containing a P-113 peptide, wherein the P-113 peptide comprises the sequence of SEQ ID NO: 1. P-113 peptide is hypoallergenic and non-cytotoxic, which means it does not cause harms or allergies to the skin and can be used as an ingredient of cosmetic products. The P-113 peptide fragment has moisture absorption and moisture retention effects, therefore it can be formulated with other ingredients of moisturizing cosmetic products, enhancing the moisturizing effect of other moisturizing ingredients. In addition, the P-113 peptide fragment is capable of inhibiting the production of MMP-9 and thus decreases collagen degradation, thereby achieving the anti-wrinkle and anti-aging effects. The cosmetic disclosed herein comprises not only the peptide, but also active ingredients of cosmetic products and essence liquid formulations.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: March 24, 2020
    Assignee: PACGEN LIFE SCIENCE CORPORATION
    Inventors: Wen-Chi Cheng, Ming-Sun Liu, Frank Lin
  • Patent number: 10589132
    Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 17, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Eldad Tzahor, Elad Bassat
  • Patent number: 10575537
    Abstract: The present invention discloses a saury Maillard peptide with antihyperuricemic activity and its preparation method and application, with the method comprising the following steps: mincing a saury, adding water, heating, agitating, adjusting a pH value to 4.2, separating by centrifugation, and collecting the precipitate; adding water, proteases and amino acids to the precipitate, adjusting a pH value to 7.0, hydrolyzing, adding a reducing sugar to cause a reaction, centrifuging and collecting a supernatant which is saury Maillard peptide; and spray drying the peptide liquid to obtain a dry powder. The method of the present invention realizes the continuous action of enzymolysis and Maillard reaction to prepare the Maillard peptide, not only simplifying the production process, shortening the production cycle, and reducing the production costs, but also significantly enhancing the antihyperuricemic activity of the produced Maillard peptide.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: March 3, 2020
    Assignee: South China University of Technology
    Inventors: Mouming Zhao, Qiangzhong Zhao, Guowan Su, Yang Liu, Lianzhu Lin, Rongzhong Zhao
  • Patent number: 10563258
    Abstract: A method for making a skin care composition by identifying connections between cosmetic agents and genes associated with one or more skin aging conditions. The method includes accessing a plurality of instances and at least one skin aging gene expression signature, comparing the at least one skin aging gene expression signature to the plurality of the instances, assigning a connectivity score to each instance based on the comparison and incorporating the cosmetic agent into a skin care composition when the connectivity score of the instance associated with the cosmetic agent has a negative correlation.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 18, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Robert Lloyd Binder, Robert Scott Youngquist, Jun Xu, Kenton Duane Juhlin, Rosemarie Osborne, Scott Michael Hartman
  • Patent number: 10561723
    Abstract: The invention relates to methods, compositions, and kits for treating a condition with an immune response modifier and a human papillomavirus (HPV) vaccine. Conditions treatable with the methods, kits and compositions include but are not limited to neoplasia, anal intraepithelial neoplasia, high-grade squamous intraepithelial neoplasia, dysplasia, anal dysplasia, dysplastic lesion, high-grade dysplastic lesion, condyloma, anal cancer, anal tumor, HPV infection, and any HPV-induced condition.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 18, 2020
    Inventor: Steven Frederick Scheibel
  • Patent number: 10561707
    Abstract: The present invention relates, according to some embodiments, method of treating eye diseases, such as AMD by administering Semaphorin 3C (Sema3C) or a variant thereof having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: February 18, 2020
    Assignees: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., RAMBAM MED-TECH LTD.
    Inventors: Shira Toledano, Ofra Kessler, Gera Neufeld, Yoreh Barak, Yelena Mumblat
  • Patent number: 10548986
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 4, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • Patent number: 10550172
    Abstract: Disclosed here are peptides derived from a serpin reactive center loop that have anti¬inflammatory, anti-atherogenic and anti-sepsis activity. Compositions containing such serpin-derived peptides are therefore useful in the treatment of transplant vascular disease and also for the treatment of hemorrhagic viral infections as well as lethal viral, fungal or bacterial sepsis in patients.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 4, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Alexandra Rose Lucas
  • Patent number: 10550151
    Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: February 4, 2020
    Assignee: Yale University
    Inventors: William C. Sessa, Frank J. Giordano
  • Patent number: 10544196
    Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 28, 2020
    Assignee: Good T Cells, Inc.
    Inventor: Sang-Kyou Lee
  • Patent number: 10537608
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 21, 2020
    Assignee: ALLYSTA PHARMACEUTICALS, INC.
    Inventor: Henry Hsu
  • Patent number: 10525101
    Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: January 7, 2020
    Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gil Benedek, Roberto Meza-Romero